- Home
- LFCR vs AMRN Comparison
LFCR vs AMRN Comparison
Compare LFCR & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LFCR | AMRN |
|---|---|---|
| Founded | 1986 | 1989 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 241.8M | 287.9M |
| IPO Year | 1996 | 1998 |
Fundamental Metrics
Financial Performance| Metric | LFCR | AMRN |
|---|---|---|
| Price | $6.40 | $11.35 |
| Analyst Decision | Hold | Strong Sell |
| Analyst Count | 5 | 2 |
| Target Price | $6.28 | ★ $12.50 |
| AVG Volume (30 Days) | ★ 411.7K | 73.0K |
| Earning Date | 11-04-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $557,559,000.00 | $181,104,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.97 | $3.11 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 6.36 | ★ 39.22 |
| 52 Week Low | $3.63 | $11.25 |
| 52 Week High | $8.98 | $17.31 |
Technical Indicators
Market Signals| Indicator | LFCR | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 62.80 | 36.60 |
| Support Level | $6.32 | N/A |
| Resistance Level | $6.50 | $15.34 |
| Average True Range (ATR) | 0.05 | 0.47 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 41.46 | 1.63 |
Price Performance
Historical ComparisonAbout LFCR Lifecore Biomedical Inc.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.